Rockefeller Capital Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.18M | Buy |
29,156
+1,890
| +7% | +$371K | 0.01% | 882 |
|
|
2026
Q1 | $5.34M | Sell |
27,266
-2,056
| -7% | -$399K | 0.01% | 896 |
|
|
2025
Q4 | $5.09M | Sell |
29,322
-75,894
| -72% | -$13.8M | 0.01% | 876 |
|
|
2025
Q3 | $20.1M | Sell |
105,216
-2,070
| -2% | -$367K | 0.04% | 417 |
|
|
2025
Q2 | $19.3M | Buy |
107,286
+90,142
| +526% | +$15.7M | 0.04% | 398 |
|
|
2025
Q1 | $2.9M | Sell |
17,144
-11,175
| -39% | -$1.84M | 0.01% | 902 |
|
|
2024
Q4 | $4.27M | Sell |
28,319
-816
| -3% | -$127K | 0.01% | 766 |
|
|
2024
Q3 | $4.52M | Buy |
29,135
+10,903
| +60% | +$1.63M | 0.01% | 735 |
|
|
2024
Q2 | $2.5M | Buy |
18,232
+557
| +3% | +$76.3K | 0.01% | 897 |
|
|
2024
Q1 | $2.35M | Sell |
17,675
-8,168
| -32% | -$1.06M | 0.01% | 937 |
|
|
2023
Q4 | $3.56M | Buy |
25,843
+801
| +3% | +$105K | 0.01% | 728 |
|
|
2023
Q3 | $3.05M | Sell |
25,042
-40,244
| -62% | -$5.36M | 0.01% | 715 |
|
|
2023
Q2 | $9.18M | Buy |
65,286
+666
| +1% | +$91.8K | 0.04% | 453 |
|
|
2023
Q1 | $9.14M | Buy |
64,620
+37
| +0.1% | +$5.29K | 0.04% | 437 |
|
|
2022
Q4 | $10.1M | Sell |
64,583
-1,647
| -2% | -$237K | 0.05% | 357 |
|
|
2022
Q3 | $8.12M | Sell |
66,230
-5,096
| -7% | -$671K | 0.04% | 410 |
|
|
2022
Q2 | $9.48M | Sell |
71,326
-1,432
| -2% | -$195K | 0.05% | 359 |
|
|
2022
Q1 | $9.96M | Sell |
72,758
-3,923
| -5% | -$547K | 0.05% | 367 |
|
|
2021
Q4 | $13.3M | Buy |
76,681
+1,301
| +2% | +$198K | 0.06% | 298 |
|
|
2021
Q3 | $11M | Buy |
75,380
+20,820
| +38% | +$3.05M | 0.06% | 296 |
|
|
2021
Q2 | $7.2M | Buy |
54,560
+39,853
| +271% | +$5.22M | 0.04% | 364 |
|
|
2021
Q1 | $1.89M | Buy |
14,707
+4,316
| +42% | +$532K | 0.01% | 597 |
|
|
2020
Q4 | $1.24M | Buy |
10,391
+755
| +8% | +$92K | 0.01% | 639 |
|
|
2020
Q3 | $1.1M | Sell |
9,636
-2,722
| -22% | -$322K | 0.01% | 576 |
|
|
2020
Q2 | $1.41M | Sell |
12,358
-536
| -4% | -$56.9K | 0.01% | 470 |
|
|
2020
Q1 | $1.03M | Buy |
12,894
+5,321
| +70% | +$551K | 0.01% | 474 |
|
|
2019
Q4 | $809K | Sell |
7,573
-104
| -1% | -$10.8K | 0.01% | 487 |
|
|
2019
Q3 | $821K | Buy |
7,677
+598
| +8% | +$61.4K | 0.01% | 423 |
|
|
2019
Q2 | $721K | Sell |
7,079
-1,892
| -21% | -$182K | 0.01% | 390 |
|
|
2019
Q1 | $806K | Buy |
8,971
+1,971
| +28% | +$171K | 0.01% | 413 |
|
|
2018
Q4 | $583K | Sell |
7,000
-6,654
| -49% | -$624K | 0.01% | 302 |
|
|
2018
Q3 | $1.47M | Sell |
13,654
-3,187
| -19% | -$350K | 0.02% | 186 |
|
|
2018
Q2 | $1.85M | Sell |
16,841
-188,882
| -92% | -$19.7M | 0.03% | 173 |
|
|
2018
Q1 | $20.6M | Buy |
+205,723
| New | +$21.1M | 0.34% | 75 |
|
Other funds holding DGX
EIG
Rockefeller Capital Management's DGX Position: Q2 2026 in Review
Rockefeller Capital Management increased its Quest Diagnostics (DGX) stake by 6.9% in Q2 2026, buying an estimated $371K and bringing the position to 29,156 shares worth $6.18M. The position accounts for 0.01% of the portfolio, ranked #882.
Rockefeller Capital Management first reported a position in DGX in Q1 2018 and has held it in 34 quarters since. The position peaked at $20.6M in Q1 2018. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Rockefeller Capital Management held 29,156 shares of Quest Diagnostics worth $6.18M as of Q2 2026.
- Rockefeller Capital Management bought 1,890 Quest Diagnostics shares in Q2 2026, an estimated $371K.
- Quest Diagnostics made up 0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #882 holding.
- Rockefeller Capital Management first reported a position in Quest Diagnostics in Q1 2018 and has held it in 34 quarters since.
- Rockefeller Capital Management's Quest Diagnostics position peaked at $20.6M in Q1 2018.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.